Windtree Therapeutics announces istaroxime presentation on Phase 2b study

Windtree Therapeutics (WINT) announced that an istaroxime presentation featuring the positive Phase 2b SEISMiC study was given on February 11, 2025 at the Technology and Heart Failure Therapeutics Conference in Boston, MA. “We continue to see interest in istaroxime from cardiologists around the world in treating cardiogenic shock,” said Dr. Steve Simonson, CMO and SVP of Windtree. “Windtree has prioritized cardiogenic shock as an initial indication target because of the unique profile of istaroxime effects and the positive Phase 2 studies in early cardiogenic shock. There is substantial unmet need for this patient population as currently available drugs can have unwanted side effects and poor outcomes. We are encouraged by the profile of istaroxime and look forward to progressing istaroxime toward Phase 3 in cardiogenic shock.”